<DOC>
	<DOCNO>NCT01222143</DOCNO>
	<brief_summary>This phase I/II open-label study evaluate toxicity efficacy nilotinib combine mitoxantrone , etoposide , high-dose cytarabine ( NOVE-HiDAC ) chemotherapy patient poor-risk acute myeloid leukemia ( AML ) . There two part study . The first part ( Phase I ) determine maximum dose nilotinib safely give combine NOVE-HiDAC . This dose use combination NOVE-HiDAC regimen second part study ( Phase II ) , evaluate antileukemic activity treatment . The patient achieve complete remission induction therapy ( 1 cycle ) receive consolidation therapy combine nilotinib ( maximum 2 cycle ) . The patient population study AML fall poor risk category . This mean persistent leukemia induction therapy , relapse within two year achieve complete remission induction therapy , certain poor risk feature diagnosis . The AML cell also positive c-kit ( stem cell factor receptor ) , involved cancer cell growth . Nilotinib drug block effect c-kit . Using drug combination chemotherapy may improve ability chemotherapy drug kill leukemia cell . This may increase chance leukemia go complete remission .</brief_summary>
	<brief_title>Safety Efficacy Study Nilotinib Combined With Mitoxantrone , Etoposide , High-dose Cytarabine Induction Chemotherapy Followed Consolidation Patients With C-kit Positive Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>AML define WHO ( World Health Organization ) criterion , subtypes except APL ( acute promyelocytic leukemia ) . One follow poor risk feature : 1 . Persistent leukemia ( least 10 % bone marrow blast ) induction therapy , consist cytarabine 100200 mg/m2 plus anthracycline . 2 . Relapse within two year achieve complete remission induction therapy . Any consolidation therapy acceptable , include stem cell transplantation . 3 . No prior induction , antecedent myeloproliferative disorder CMML ( chronic myelomonocytic leukemia ) ( These patient give NOVEHiDAC frontline therapy Princess Margaret Hospital ) . Positivity ckit ( CD117 ) least 30 % blast measure flow cytometry . For relapsed patient , assessed time relapse . For primary induction failures initial diagnostic sample may use . Age 1865 . ECOG performance status &lt; 3 ( see Appendix I ) . Patients must follow laboratory value within normal limit ( WNL ) local institution lab correct WNL supplement prior first dose study medication . 1 . Potassium ( WNL ) 2 . Magnesium ( WNL ) No chemotherapy within previous four week , hydroxyurea control count . Hydroxyurea may continue Day 4 treatment nilotinib . If hydroxyurea use , must stop least 48 hour prior start chemotherapy . Able give inform consent . Active uncontrolled infection . Active CNS ( central nervous system ) leukemia Serum creatinine &gt; 200 umol/L . Serum bilirubin &gt; 1.5 x ULN , AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &gt; 2x ULN ( upper limit normal ) . Serum amylase lipase &gt; 1.5x ULN Left ventricular ejection fraction &lt; 50 % Impaired cardiac function include follow : 1 . Long QT syndrome know family history long QT syndrome 2 . History presence clinically significant ventricular atrial tachyarrhythmias 3 . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) 4 . Inability monitor QT interval ECG 5 . QTc &gt; 450 msec baseline ECG ( electrocardiogram ) . If QTc &gt; 450 electrolyte within normal range , electrolyte correct patient rescreened QTc 6 . Myocardial infarction within 1 year start study drug 7 . Other clinically significant heart disease ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension ) Patients currently receive treatment strong CYP3A4 inhibitor list Section 5.8 treatment either discontinue switched different medication prior start study drug . Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug History acute chronic pancreatic disease . Women pregnant , breast feeding , childbearing potential without negative serum test baseline . Male female patient childbearing potential unwilling use contraceptive precaution throughout trial 3 month follow discontinuation study drug . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Women childbearing potential must negative serum pregnancy test prior first dose nilotinib . Known hypersensitivity study drug component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>NOVE-HiDAC</keyword>
	<keyword>Nilotinib</keyword>
</DOC>